Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Glac Biotech Co. Ltd. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. Both of these pending matters are located within 1 distinct art unit. This concentration suggests that the company's current biotechnology applications are focused on a specific technical area that falls under the jurisdiction of a single art unit at the patent office.
GOUGH, TIFFANY MAUREEN is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Since there are 2 pending office actions and 2 distinct examiners, the workload is split evenly between them. Each examiner manages 1 of the 2 pending actions, providing a balanced approach to the company's current prosecution within the Biotechnology & Pharmaceuticals sector.
The use of 1 distinct art unit for all pending actions may allow for a more consistent prosecution strategy across the company's current filings. Practitioners should also evaluate the 2 distinct examiners to see if their individual examination styles differ despite being in the same art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOUGH, TIFFANY MAUREEN | 1 | 31.6% | +46.8% |
| EDWARDS, JESSICA FAYE | 1 | 39.1% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18806076 | METHOD FOR INCREASING CALCIUM ABSORPTION USING CULTURE OF LACTOBACILLUS PLANTARUM PL-02 | GOUGH, TIFFANY MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18806076 | METHOD FOR INCREASING CALCIUM ABSORPTION USING CULTURE OF LACTOBACILLUS PLANTARUM PL-02 | GOUGH, TIFFANY MAUREEN | — |
| 18444872 | USE OF LACTOBACILLUS PLANTARUM STRAIN, ITS METABOLITE, OR COMPOSITION CONTAINING THE SAME STRAIN FOR REPAIRING OR PREVENTING RETINAL DAMAGE | EDWARDS, JESSICA FAYE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18806076 | METHOD FOR INCREASING CALCIUM ABSORPTION USING CULTURE OF LACTOBACILLUS PLANTARUM PL-02 | GOUGH, TIFFANY MAUREEN | — | §102§103§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18444872 | USE OF LACTOBACILLUS PLANTARUM STRAIN, ITS METABOLITE, OR COMPOSITION CONTAINING THE SAME STRAIN FOR REPAIRING OR PREVENTING RETINAL DAMAGE | EDWARDS, JESSICA FAYE | 1657 | §103§112DP | Non-Final OA | — | Pending | Feb 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial